A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy

Trial Profile

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Lampalizumab (Primary)
  • Indications Age-related macular degeneration; Atrophy
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 08 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Jun 2017.
    • 03 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top